Yuetiva K. Deming

The paper uses BADGERS to identify risk factors and endophenotypes for late-onset Alzheimer's disease by analyzing biobank-wide data.

The paper develops an APOE genetic risk score based on neuropathology that better explains CSF biomarker variance than traditional APOE ε4 metrics.

The paper performs a metabolome-wide association study to identify CSF metabolite-phenotype associations in neurological and psychiatric disorders.

The paper identifies CSF metabolites associated with tau levels and shows they improve prediction of Alzheimer's disease status.

The paper develops a polygenic risk score integrating AD biomarkers and shows it better predicts cognitive decline than a clinical AD-based PRS.

This study identifies genetic variants in the MS4A gene cluster associated with higher sTREM2 levels and reduced Alzheimer disease risk, suggesting MS4A4A regulates sTREM2 and contributes to AD pathogenesis.

The paper identifies a genetic variant in TMEM106B associated with increased neuronal proportion in neurodegenerative and cognitive normal cohorts, suggesting a role in neuronal protection.

This study evaluates gene-based methods for family-based analyses of familial late-onset Alzheimer disease, identifying novel candidate genes.

The paper constructs polygenic risk scores for sporadic late-onset Alzheimer's Disease and finds shared genetic architecture with familial and early-onset forms, showing varying odds ratios across cohorts.

This study identifies a haplotype lowering PU.1 expression in myeloid cells that delays Alzheimer’s disease onset by affecting gene expression and function.